China welcomes the resumption of Nvidia H20 AI chip sales. Japan warns tariffs “Not Right Tool” – Business Live | Work

AI For Business


Introduction: China says that “twin cooperation is the right path” as the nvidia H20 sales have been cleared

Good morning, welcome to comprehensive coverage of business, financial markets and the global economy.

US-China relations appear to have warmed a bit after chipmakers nvidia A green light was given to Washington to resume sales of H20 AI chips to Chinese companies.

nvidia's CEO, Jensen Hanearlier this week, the US government revealed that his company had been granted a license to sell H20 chips to China, and that delivery would start soon.

This reverses restrictions announced in April when the White House announced stricter controls on exports of computer chips used in artificial intelligence.

And today, Beijing welcomes this change of mind, confirming that the US has “taken an initiative” to approve the sale of H20 again.

China's Commerce Ministry said in a statement that “victory cooperation” is the right path to collapse and that it hopes that both countries can “meet along the way” and cooperate.

The ministry also urged the US to abandon its “zero-sum mentality” and cancel “irrational” trade restrictions on China, warning that “control” would not lead to a solution.

The H20 Graphic Processing Unit (GPU) is an advanced chip used in AI systems. However, it is less powerful than today's top Nvidia semiconductors, as it is designed to comply with US restrictions for exporting AI chips to China.

Earlier this week, Commerce Secretary Howard Lutnick revealed that updated sales of H20 chips to China are linked to rare earth magnet trading. He also claimed that Nvidia would only sell China “fourth-best” chips.

Still, the prospect of increased sales to China brought Nvidia's shares to a high this week.

Orders from Chinese companies for H20 chips must be sent from Nvidia to the US government for approval.

Agenda

  • 9.30am BST: UK bankruptcy data

  • 10am BST: Eurozone construction output data for May

  • 1:30pm BST: US homes start data for June

  • 3pm BST: University of Michigan Consumer Trust Report

Share

Important Events

Pharmaceuticals Firm GSK shares fell more than 6% in early trading after hematologic cancer drug Brenrep grabbed regulatory hurdles in the US.

Yesterday, the US FDA's Independent Advisors Panel recommended it to Brenrep, citing previous concerns about eye-related side effects.

GSK He told the city it was confident in Blenrep's profit/risk profile, and told it would continue to work closely with the FDA in completing its drug reviews. Final decisions on whether to approve the drug will be rested at the FDA. The FDA will consider the views of the Oncology Drug Advisory Committee (ODAC) that voted 5-3 against Blenrep.

The company added that in some markets, including the UK and Japan, the Blenrep combination has been approved for refractory multiple myeloma (cancer that does not respond to treatment), and applications in other markets, including the EU and China are being reviewed.

Share

Updated with





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *